| Literature DB >> 29452639 |
Giuseppe Arena1, Madi Yann Cissé2, Samuel Pyrdziak2, Laurent Chatre3, Romain Riscal2, Maryse Fuentes2, Jamie Jon Arnold4, Markus Kastner4, Laurie Gayte2, Christelle Bertrand-Gaday5, Kevin Nay5, Claire Angebault-Prouteau6, Kerren Murray7, Beatrice Chabi5, Christelle Koechlin-Ramonatxo5, Béatrice Orsetti2, Charles Vincent2, François Casas5, Jean-Christophe Marine8, Sandrine Etienne-Manneville7, Florence Bernex9, Anne Lombès10, Craig Eugene Cameron4, Hervé Dubouchaud11, Miria Ricchetti3, Laetitia Karine Linares12, Laurent Le Cam13.
Abstract
Accumulating evidence indicates that the MDM2 oncoprotein promotes tumorigenesis beyond its canonical negative effects on the p53 tumor suppressor, but these p53-independent functions remain poorly understood. Here, we show that a fraction of endogenous MDM2 is actively imported in mitochondria to control respiration and mitochondrial dynamics independently of p53. Mitochondrial MDM2 represses the transcription of NADH-dehydrogenase 6 (MT-ND6) in vitro and in vivo, impinging on respiratory complex I activity and enhancing mitochondrial ROS production. Recruitment of MDM2 to mitochondria increases during oxidative stress and hypoxia. Accordingly, mice lacking MDM2 in skeletal muscles exhibit higher MT-ND6 levels, enhanced complex I activity, and increased muscular endurance in mild hypoxic conditions. Furthermore, increased mitochondrial MDM2 levels enhance the migratory and invasive properties of cancer cells. Collectively, these data uncover a previously unsuspected function of the MDM2 oncoprotein in mitochondria that play critical roles in skeletal muscle physiology and may contribute to tumor progression.Entities:
Keywords: MDM2; MT-ND6; hypoxia; migration; mitochondria; respiratory complex I
Mesh:
Substances:
Year: 2018 PMID: 29452639 DOI: 10.1016/j.molcel.2018.01.023
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970